ATE518842T1 - Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten - Google Patents

Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten

Info

Publication number
ATE518842T1
ATE518842T1 AT09003174T AT09003174T ATE518842T1 AT E518842 T1 ATE518842 T1 AT E518842T1 AT 09003174 T AT09003174 T AT 09003174T AT 09003174 T AT09003174 T AT 09003174T AT E518842 T1 ATE518842 T1 AT E518842T1
Authority
AT
Austria
Prior art keywords
contain
pharmaceutical compositions
production process
medicinal products
vitronectin receptor
Prior art date
Application number
AT09003174T
Other languages
English (en)
Inventor
Jean-Marie Ruxer
Jean-Michel Lefrancois
Bertrand Heckmann
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Application granted granted Critical
Publication of ATE518842T1 publication Critical patent/ATE518842T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT09003174T 2002-11-19 2003-11-12 Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten ATE518842T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant

Publications (1)

Publication Number Publication Date
ATE518842T1 true ATE518842T1 (de) 2011-08-15

Family

ID=32187700

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09003174T ATE518842T1 (de) 2002-11-19 2003-11-12 Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten
AT03799611T ATE431825T1 (de) 2002-11-19 2003-11-12 Neue antagonisten für den vitronectinrezeptor, verfahren zu deren herstellung, deren verwendung als arzneimittel und pharmazeutische zusammensetzung, die diese enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03799611T ATE431825T1 (de) 2002-11-19 2003-11-12 Neue antagonisten für den vitronectinrezeptor, verfahren zu deren herstellung, deren verwendung als arzneimittel und pharmazeutische zusammensetzung, die diese enthalten

Country Status (27)

Country Link
US (2) US7582640B2 (de)
EP (2) EP2070914B1 (de)
JP (1) JP4567459B2 (de)
KR (1) KR101140752B1 (de)
CN (2) CN1738817B (de)
AR (2) AR042068A1 (de)
AT (2) ATE518842T1 (de)
AU (2) AU2003299330B2 (de)
BR (1) BR0316307A (de)
CA (1) CA2506310C (de)
CO (1) CO5700761A2 (de)
CY (1) CY1112218T1 (de)
DE (1) DE60327712D1 (de)
DK (2) DK2070914T3 (de)
ES (2) ES2325616T3 (de)
FR (1) FR2847254B1 (de)
IL (2) IL168136A (de)
MA (1) MA27492A1 (de)
MX (1) MXPA05005340A (de)
NO (1) NO20052491D0 (de)
PL (1) PL376866A1 (de)
PT (2) PT1565467E (de)
RU (1) RU2412185C2 (de)
SI (2) SI2070914T1 (de)
TW (1) TW200412969A (de)
WO (1) WO2004048375A1 (de)
ZA (1) ZA200502850B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
ES2836733T3 (es) 2018-08-17 2021-06-28 Oxurion NV Antagonistas de integrina
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A4 (de) 2020-06-29 2024-07-24 Ickovic & Bliss, Inc. Systeme, verfahren und programmprodukte zur digitalen pet-identifizierung

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
EP0667773A4 (de) 1992-10-14 1996-09-25 Merck & Co Inc Fibrinogen-rezeptor-antagonisten.
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
ATE227567T1 (de) 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0907637A1 (de) 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP0933367A1 (de) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Acylguanidin Derivate als Inhibitoren von Knochenaufsauge und als Vitronectin Rezeptor Antagonisten
BR9907735A (pt) 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
WO1999050249A2 (en) * 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6458814B1 (en) * 1998-08-07 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP1194151A4 (de) 1999-06-23 2003-01-15 Merck & Co Inc Antagonisten der integrin rezeptoren
EP1065208A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituierte Purin Derivate als Inhibitoren der Zell-Adhäsion
EP1065207A1 (de) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
EP1218095B1 (de) * 1999-10-05 2003-09-03 Element Six (Pty) Ltd Wachstum von diamantclustern
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
JP4567459B2 (ja) 2010-10-20
IL205693A (en) 2011-06-30
EP1565467B1 (de) 2009-05-20
SI2070914T1 (sl) 2012-02-29
US7582640B2 (en) 2009-09-01
FR2847254B1 (fr) 2005-01-28
DK2070914T3 (da) 2011-11-21
SI1565467T1 (sl) 2009-10-31
PT2070914E (pt) 2011-10-12
CA2506310C (fr) 2014-04-08
CN101928287A (zh) 2010-12-29
ES2325616T3 (es) 2009-09-10
EP2070914B1 (de) 2011-08-03
EP1565467A1 (de) 2005-08-24
PT1565467E (pt) 2009-07-15
AU2003299330A1 (en) 2004-06-18
ATE431825T1 (de) 2009-06-15
ZA200502850B (en) 2005-10-25
CO5700761A2 (es) 2006-11-30
CY1112218T1 (el) 2015-12-09
PL376866A1 (pl) 2006-01-09
EP2070914A1 (de) 2009-06-17
AU2003299330B2 (en) 2009-09-17
BR0316307A (pt) 2005-09-27
TW200412969A (en) 2004-08-01
NO20052491L (no) 2005-05-23
AR077476A2 (es) 2011-08-31
ES2369561T3 (es) 2011-12-01
CA2506310A1 (fr) 2004-06-10
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
DK1565467T3 (da) 2009-09-14
KR20050083926A (ko) 2005-08-26
AR042068A1 (es) 2005-06-08
IL168136A (en) 2012-06-28
WO2004048375A1 (fr) 2004-06-10
DE60327712D1 (de) 2009-07-02
MXPA05005340A (es) 2005-11-17
CN1738817A (zh) 2006-02-22
AU2009212779A1 (en) 2009-09-17
NO20052491D0 (no) 2005-05-23
HK1076277A1 (en) 2006-01-13
CN1738817B (zh) 2011-12-21
HK1129372A1 (en) 2009-11-27
RU2412185C2 (ru) 2011-02-20
AU2009212779B2 (en) 2011-09-01
FR2847254A1 (fr) 2004-05-21
US20060052398A1 (en) 2006-03-09
US20090149476A1 (en) 2009-06-11
RU2005119163A (ru) 2006-02-27
KR101140752B1 (ko) 2012-05-03
JP2006508999A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE469152T1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ATE353900T1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
ATE316526T1 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
IL189578A (en) Pyridine derivatives, pharmaceutical compounds containing them, and their use in the preparation of drugs for the treatment of cns diseases
GB0428475D0 (en) Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
MXPA04001645A (es) Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales.
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
IL179611A (en) History 1-Aza-bicycloalkyl, their process, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of psychotic disorders
IL176236A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
ATE489382T1 (de) Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
DE69715009D1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten
ZA200702397B (en) Benzoxasine and quinoxaline derivatives and uses
ATE323694T1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
WO2004046096A3 (en) Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics
EP1782824A3 (de) Pharmazeutische Zusammensetzungen, die Diaminooxidase enthalten
IL166098A0 (en) 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
ITRM20030394A1 (it) Uso dell'indometacina e derivati come farmaci antivirali e relative composizioni farmaceutiche.
DE602007002591D1 (de) Neue Naphtalinderivate, ihr Herstellungsverfahren und die pharmazeutischen Zusammensetzungen, die sie enthalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2070914

Country of ref document: EP